[Chronic lymphocytic leukaemia: current management].
BACKGROUND
Chronic lymphocytic leukemia (CLL) is the most common leukaemia in the Western world. Recent advancement in the aetiology, pathophysiology and the development of new therapeutics tools have significantly modified the current management of CLL.


BACKGROUND
The cellular origin of CLL is still unknown. The current main hypothesis will be first briefly described. This review will then focus on the newly defined prognostic factors and the development and use of new drugs for the treatment of CLL. To describe the modern and practical management of CLL, we will compare classical and new prognostic markers. Then, we will discuss the various therapeutic options including chemotherapy and immunotherapy (monoclonal antibodies, allogenic transplantation), and define their current respective indications.


CONCLUSIONS
These new diagnostic and prognostic markers will allow the characterization of new prognostic subgroups of patients. This will lead to a targeted and individualized therapeutic approach. We will present the first results of clinical trials and the on-going studies conducted in this disease.
Aurran-Schleinitz
T
T
Département d'onco-hématologie, institut Paoli-Calmettes, boulevard Sainte Marguerite, 13273 Marseille cedex 9, France. aurrant@marseille.fnclcc.fr
Arnoulet
C
C
Ivanov
V
V
Coso
D
D
Rey
J
J
Schiano
J-M
JM
Stoppa
A-M
AM
Bouabdallah
R
R
Gastaut
J-A
JA
D000970:Antineoplastic Agents / Q000627:therapeutic use; D006801:Humans; D015994:Incidence; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy* / Q000453:epidemiology / Q000401:mortality; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors; D016019:Survival Analysis
D000970:Antineoplastic Agents